Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

del Rincón, 2001, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors, Arthritis Rheum, 44, 2737, 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#

Maradit-Kremers, 2005, Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study, Arthritis Rheum, 52, 402, 10.1002/art.20853

Gonzalez-Juanatey, 2003, Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease, Medicine (Baltimore), 82, 407, 10.1097/01.md.0000101572.76273.60

Libby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161/hc0902.104353

Mudau, 2012, Endothelial dysfunction: the early predictor of atherosclerosis, Cardiovasc J Afr, 23, 222, 10.5830/CVJA-2011-068

Gonzalez-Juanatey, 2011, Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease, Arthritis Res Ther, 13, R101, 10.1186/ar3382

Steyers, 2014, Endothelial dysfunction in chronic inflammatory diseases, Int J Mol Sci, 15, 11324, 10.3390/ijms150711324

Khandpur, 2013, NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis, Sci Transl Med, 5, 178ra40, 10.1126/scitranslmed.3005580

Brinkmann, 2004, Neutrophil extracellular traps kill bacteria, Science, 303, 1532, 10.1126/science.1092385

Steinberg, 2007, Unconventional roles of the NADPH oxidase: signaling, ion homeostasis, and cell death, Sci STKE, 379, pe11

Darrah, 2012, NETs: the missing link between cell death and systemic autoimmune diseases?, Front Immunol, 3, 428

Barbarroja, 2014, Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis, Arterioscler Thromb Vasc Biol, 34, 2706, 10.1161/ATVBAHA.114.304475

Gratchev, 2012, Monocytes as a diagnostic marker of cardiovascular diseases, Immunobiology, 217, 476, 10.1016/j.imbio.2012.01.008

Orme, 2012, Macrophages and neutrophils in systemic lupus erythematosus—an online molecular catalog, Autoimmun Rev, 11, 365, 10.1016/j.autrev.2011.10.010

Lioté, 1996, Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release, Clin Exp Immunol, 106, 13, 10.1046/j.1365-2249.1996.d01-820.x

Kinne, 2007, Cells of the synovium in rheumatoid arthritis. Macrophages, Arthritis Res Ther, 9, 224, 10.1186/ar2333

Goronzy, 2009, Developments in the scientific understanding of rheumatoid arthritis, Arthritis Res Ther, 1, 249, 10.1186/ar2758

Rubbert-Roth, 2009, Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review, Arthritis Res Ther, 11, S1, 10.1186/ar2666

Protogerou, 2011, A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis, Atherosclerosis, 219, 734, 10.1016/j.atherosclerosis.2011.09.015

Choy, 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, Rheumatology (Oxford), 51 Suppl 5, v3, 10.1093/rheumatology/kes113

Ogura, 2008, Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction, Immunity, 29, 628, 10.1016/j.immuni.2008.07.018

Samson, 2012, Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis, Arthritis Rheum, 64, 2499, 10.1002/art.34477

Nishimoto, 2008, Humanized antihuman IL-6 receptor antibody, tocilizumab, Handb Exp Pharmacol, 181, 151, 10.1007/978-3-540-73259-4_7

Aletaha, 2010, 2010 Rheumatoid Arthritis Classification criteria. An American College of Rheumatology/European League against rheumatism collaborative initiative, Arthritis Rheum, 62, 2569, 10.1002/art.27584

Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107

Farley, 2012, A SerpinB1 regulatory mechanism is essential for restricting NETosis, J Immunol, 189, 4574, 10.4049/jimmunol.1201167

Yan, 2016, Neutrophil proteases promote experimental abdominal aortic aneurysm via extracellular trap release and plasmacytoid dendritic cell activation, Arterioscler Thromb Vasc Biol, 36, 1660, 10.1161/ATVBAHA.116.307786

Carmona-Rivera, 2013, Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity, Semin Immunopathol, 35, 455, 10.1007/s00281-013-0375-7

Malemud, 2013, Intracellular signaling pathways in rheumatoid arthritis, J Clin Cell Immunol, 4, 160, 10.4172/2155-9899.1000160

Iannone, 2016, Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis, Clin Rheumatol, 35, 19, 10.1007/s10067-015-3120-x

Strang, 2013, Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis, Atherosclerosis, 229, 174, 10.1016/j.atherosclerosis.2013.04.031

Gabay, 2016, Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1806, 10.1136/annrheumdis-2015-207872

Provan, 2015, The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab, PLoS One, 10, e0130709, 10.1371/journal.pone.0130709

Souto, 2015, Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis, Arthritis Rheumatol, 67, 117, 10.1002/art.38894

Kume, 2011, Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial, J Rheumatol, 38, 2169, 10.3899/jrheum.110340

Nishimoto, 2009, Mod Rheumatol, 19, 12, 10.3109/s10165-008-0125-1

Suzuki, 2010, Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule, Rheumatol Int, 30, 309, 10.1007/s00296-009-0953-0

Kageyama, 2008, Reduction of oxidative stress marker levels by anti-TNFalpha antibody, infliximab, in patients with rheumatoid arthritis, Clin Exp Rheumatol, 26, 73

Kageyama, 2008, Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis, Rheumatol Int, 28, 245, 10.1007/s00296-007-0419-1

Hirao, 2012, Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab, Rheumatol Int, 32, 4041, 10.1007/s00296-011-2135-0

Gualtierotti, 2016, Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade, Clin Exp Rheumatol, 34, 451

McInnes, 2015, Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study, Ann Rheum Dis, 74, 694, 10.1136/annrheumdis-2013-204345

Tono, 2015, Effects of anti-IL-6 receptor antibody on human monocytes, Mod Rheumatol, 25, 79, 10.3109/14397595.2014.914016

Nishimoto, 2008, Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease, Blood, 112, 3959, 10.1182/blood-2008-05-155846

Bozza, 2009, Leukocyte lipid bodies-biogenesis and functions in inflammation, Biochim Biophys Acta, 1791, 540, 10.1016/j.bbalip.2009.01.005

Herker, 2012, Emerging role of lipid droplets in host/pathogen interactions, J Biol Chem, 287, 2280, 10.1074/jbc.R111.300202

Okamoto, 2011, Tyrosine kinases in rheumatoid arthritis, J Inflamm (Lond), 8, 21, 10.1186/1476-9255-8-21

Chowdhury, 2014, Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility, Arthritis Res Ther, 16, R122, 10.1186/ar4579

Biffl, 1995, Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent, J Leukoc Biol, 58, 5824, 10.1002/jlb.58.5.582

Afford, 1992, The induction by human interleukin-6 of apoptosis in the promonocytic cell line u937 and human neutrophils, J Biol Chem, 267, 216126, 10.1016/S0021-9258(19)36655-4

McNamee, 2005, Effect of pro-inflammatory cytokines on spontaneous apoptosis in leukocyte sub-sets within a whole blood culture, Cytokine, 31, 1617, 10.1016/j.cyto.2005.05.001

Wright, 2016, Low-density granulocytes: functionally distinct, immature neutrophils in rheumatoid arthritis with altered properties and defective TNF signaling, J Leukoc Biol

Denny, 2010, A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induced vascular damage and synthesizes type I IFNs, J Immunol, 184, 3284, 10.4049/jimmunol.0902199